Influence of renal function and platelet turnover on the antiplatelet effect of aspirin

Thrombosis Research

Volumn 129, Issue 4, 2012, Pages 434-440

  Würtz, Morten ^a   Wulff, Lise N ^a   Grove, Erik L ^a   Kristensen, Steen D ^a   Hvas, Anne Mette ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Aspirin; Platelet aggregation; Platelet function tests; Platelet turnover; Renal insufficiency; von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; COLLAGEN; CREATININE; CYSTATIN C; THROMBOXANE B2; VON WILLEBRAND FACTOR;

ADULT; ANALYTIC METHOD; ARTICLE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ELECTRODE AGGREGOMETRY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE LIFESPAN;

AGED; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; TREATMENT OUTCOME;

EID: 84858333752     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.07.019     Document Type: Article

References (41)

1. B.F. Culleton, M.G. Larson, P.W. Wilson, J.C. Evans, P.S. Parfrey, and D. Levy Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency Kidney Int 56 6 1999 2214 2219
2. M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, J. Coresh, B. Culleton, and L.L. Hamm Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation 108 17 2003 2154 2169
3. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 13 2004 1296 1305
4. T.J. Rabelink, J.J. Zwaginga, H.A. Koomans, and J.J. Sixma Thrombosis and hemostasis in renal disease Kidney Int 46 2 1994 287 296
5. A. Thijs, P.W. Nanayakkara, P.M. Ter Wee, P.C. Huijgens, van GC, and C.D. Stehouwer Mild-to-moderate renal impairment is associated with platelet activation: a cross-sectional study Clin Nephrol 70 4 2008 325 331
6. M.J. Landray, D.C. Wheeler, G.Y. Lip, D.J. Newman, A.D. Blann, and F.J. McGlynn Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study Am J Kidney Dis 43 2 2004 244 253
7. P.J. Mason, A.K. Jacobs, and J.E. Freedman Aspirin resistance and atherothrombotic disease J Am Coll Cardiol 46 6 2005 986 993
8. E.L. Grove, and S.D. Kristensen Update on oral antiplatelet therapy: principles, problems and promises Future Cardiol 5 3 2009 247 258
9. J.D. Snoep, M.M. Hovens, J.C. Eikenboom, J.G. van der Bom, and M.V. Huisman Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis Arch Intern Med 167 15 2007 1593 1599
10. G. Krasopoulos, S.J. Brister, W.S. Beattie, and M.R. Buchanan Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis BMJ 336 7637 2008 195 198
11. S. Guthikonda, C.L. Alviar, M. Vaduganathan, M. Arikan, A. Tellez, and T. DeLao Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease J Am Coll Cardiol 52 9 2008 743 749
12. S. Guthikonda, E.I. Lev, R. Patel, T. DeLao, A.L. Bergeron, and J.F. Dong Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin J Thromb Haemost 5 3 2007 490 496
13. E.L. Grove, A.M. Hvas, S.B. Mortensen, S.B. Larsen, and S.D. Kristensen Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease J Thromb Haemost 9 1 2011 185 191
14. P. Harrison, M.S. Robinson, I.J. Mackie, and S.J. Machin Reticulated platelets Platelets 8 6 1997 379 383
15. P.M. Mannucci von Willebrand factor: a marker of endothelial damage? Arterioscler Thromb Vasc Biol 18 9 1998 1359 1362
16. A.D. Blann Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years Thromb Haemost 95 1 2006 49 55
17. P.H. Whincup, J. Danesh, M. Walker, L. Lennon, A. Thomson, and P. Appleby von Willebrand factor and coronary heart disease: prospective study and meta-analysis Eur Heart J 23 22 2002 1764 1770
18. E.L. Grove, A.M. Hvas, and S.D. Kristensen Immature platelets in patients with acute coronary syndromes Thromb Haemost 101 1 2009 151 156
19. S.B. Mortensen, S.B. Larsen, E.L. Grove, S.D. Kristensen, and A.M. Hvas Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus Thromb Res 126 4 2010 318 322
20. A.S. Levey, J. Coresh, T. Greene, L.A. Stevens, Y.L. Zhang, and S. Hendriksen Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate Ann Intern Med 145 4 2006 247 254
21. C. Briggs, S. Kunka, D. Hart, S. Oguni, and S.J. Machin Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia Br J Haematol 126 1 2004 93 99
22. O. Toth, A. Calatzis, S. Penz, H. Losonczy, and W. Siess Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood Thromb Haemost 96 6 2006 781 788
23. D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, and A. Schomig Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 10 2009 849 856
24. H.L. Nielsen, S.D. Kristensen, S.S. Thygesen, J. Mortensen, S.B. Pedersen, and E.L. Grove Aspirin response evaluated by the VerifyNow Aspirin System and Light Transmission Aggregometry Thromb Res 123 2008 267 273
25. M. Cleanthis, J. Smout, V. Bhattacharya, H. Ashour, A. Dyker, and G.A. Ford Soluble but not platelet P-selectin correlates with spontaneous platelet aggregation: a pilot study Clin Appl Thromb Hemost 14 2 2008 227 233
26. C. Patrono, G. Ciabattoni, E. Pinca, F. Pugliese, G. Castrucci, and S.A. De Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects Thromb Res 17 3-4 1980 317 327
27. S.S. Hedegaard, A.M. Hvas, E.L. Grove, J. Refsgaard, B. Rocca, and G. Davi Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration Thromb Res 124 1 2009 96 100
28. C. Patrono, and B. Rocca Drug insight: aspirin resistance-fact or fashion? Nat Clin Pract Cardiovasc Med 4 1 2007 42 50
29. G. Remuzzi Bleeding in renal failure Lancet 1 8596 1988 1205 1208
30. G. Escolar, A. Cases, E. Bastida, M. Garrido, J. Lopez, and L. Revert Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa Blood 76 7 1990 1336 1340
31. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 6 1999 461 470
32. M.G. Shlipak, M.J. Sarnak, R. Katz, L.F. Fried, S.L. Seliger, and A.B. Newman Cystatin C and the risk of death and cardiovascular events among elderly persons N Engl J Med 352 20 2005 2049 2060
33. T. Keller, C.M. Messow, E. Lubos, V. Nicaud, P.S. Wild, and H.J. Rupprecht Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study Eur Heart J 30 3 2009 314 320
34. E.L. Grove, M. Würtz, A.M. Hvas, and S.D. Kristensen Increased platelet turnover in patients with previous definite stent thrombosis J Thromb Haemost 9 2011 1418 1419
35. S. Guthikonda, K. Mangalpally, M. Vaduganathan, R. Patel, T. DeLao, and A.L. Bergeron Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy Thromb Haemost 100 1 2008 83 89
36. M. Wurtz, E.L. Grove, L.N. Wulff, A.K. Kaltoft, H.H. Tilsted, and L.O. Jensen Patients With Previous Definite Stent Thrombosis Have a Reduced Antiplatelet Effect of Aspirin and a Larger Fraction of Immature Platelets JACC Cardiovasc Interv 3 8 2010 828 835
37. B. Rocca, P. Secchiero, G. Ciabattoni, F.O. Ranelletti, L. Catani, and L. Guidotti Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets Proc Natl Acad Sci USA 99 11 2002 7634 7639
38. J. Danesh, J.G. Wheeler, G.M. Hirschfield, S. Eda, G. Eiriksdottir, and A. Rumley C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease N Engl J Med 350 14 2004 1387 1397
39. P.A. Gurbel, D.J. Kereiakes, and V.L. Serebruany Soluble P-selectin is not a surrogate marker for platelet P-selectin: evidence from a multicenter chest pain study group J Thromb Thrombolysis 10 1 2000 15 22
40. M. Wurtz, E.L. Grove, S.D. Kristensen, and A.M. Hvas The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease Heart 96 5 2010 368 371
41. N.H. Wallen, M. Ladjevardi, J. Albert, and A. Broijersen Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin Thromb Res 87 1 1997 151 157